Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Effect of Interferon alfa-2a Treatment on Adaptive and Innate Immune Systems in Patients With Behçet Disease Uveitis.

Albayrak O, Oray M, Can F, Uludag Kirimli G, Gul A, Tugal-Tutkun I, Onal S.

Invest Ophthalmol Vis Sci. 2019 Jan 2;60(1):52-63. doi: 10.1167/iovs.18-25548.

PMID:
30601931
2.

The Collaborative Ocular Tuberculosis Study (COTS)-1: A Multinational Description of the Spectrum of Choroidal Involvement in 245 Patients with Tubercular Uveitis.

Agrawal R, Gunasekeran DV, Agarwal A, Carreño E, Aggarwal K, Gupta B, Raje D, Murthy SI, Westcott M, Chee SP, McCluskey P, Ling HS, Teoh S, Cimino L, Biswas J, Narain S, Agarwal M, Mahendradas P, Khairallah M, Jones N, Tugal-Tutkun I, Babu K, Basu S, Lee R, Al-Dhibi H, Bodaghi B, Invernizzi A, Goldstein DA, Herbort CP, Barisani-Asenbauer T, González-López JJ, Androudi S, Bansal R, Moharana B, Mahajan S, Esposti S, Tasiopoulou A, Nadarajah S, Agarwal M, Abraham S, Vala R, Lord J, Singh R, Sharma A, Sharma K, Zierhut M, Kon OM, Kempen J, Cunningham ET, Rousselot A, Nguyen QD, Pavesio C, Gupta V.

Ocul Immunol Inflamm. 2018 Aug 29:1-11. doi: 10.1080/09273948.2018.1489061. [Epub ahead of print]

PMID:
30156979
3.

Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations.

Ozguler Y, Leccese P, Christensen R, Esatoglu SN, Bang D, Bodaghi B, Çelik AF, Fortune F, Gaudric J, Gul A, Kötter I, Mahr A, Moots RJ, Richter J, Saadoun D, Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H, Hatemi G.

Rheumatology (Oxford). 2018 Dec 1;57(12):2200-2212. doi: 10.1093/rheumatology/key242.

PMID:
30107448
4.

Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome.

Leccese P, Ozguler Y, Christensen R, Esatoglu SN, Bang D, Bodaghi B, Celik AF, Fortune F, Gaudric J, Gül A, Kötter I, Mahr A, Moots RJ, Richter J, Saadoun D, Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H, Hatemi G.

Semin Arthritis Rheum. 2018 May 19. pii: S0049-0172(18)30240-3. doi: 10.1016/j.semarthrit.2018.05.008. [Epub ahead of print]

PMID:
29954598
5.

2018 update of the EULAR recommendations for the management of Behçet's syndrome.

Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, Gaudric J, Gul A, Kötter I, Leccese P, Mahr A, Moots R, Ozguler Y, Richter J, Saadoun D, Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H.

Ann Rheum Dis. 2018 Jun;77(6):808-818. doi: 10.1136/annrheumdis-2018-213225. Epub 2018 Apr 6.

PMID:
29625968
6.

Varicell Zoster Virus-Associated Uveitis.

Cunningham ET Jr, Miserocchi E, Tugal-Tutkun I, Zierhut M.

Ocul Immunol Inflamm. 2018;26(2):167-170. doi: 10.1080/09273948.2018.1444120. No abstract available.

PMID:
29498922
7.

Use of Gevokizumab in Patients with Behçet's Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study.

Tugal-Tutkun I, Pavesio C, De Cordoue A, Bernard-Poenaru O, Gül A.

Ocul Immunol Inflamm. 2018;26(7):1023-1033. doi: 10.1080/09273948.2017.1421233. Epub 2018 Jan 25.

PMID:
29370572
8.

The Collaborative Ocular Tuberculosis Study (COTS)-1 Report 3: Polymerase Chain Reaction in the Diagnosis and Management of Tubercular Uveitis: Global Trends.

Agarwal A, Agrawal R, Gunasekaran DV, Raje D, Gupta B, Aggarwal K, Murthy SL, Westcott M, Chee SP, Mccluskey P, Su Ling H, Teoh S, Cimino L, Biswas J, Narain S, Agarwal M, Mahendradas P, Khairallah M, Jones N, Tugal-Tutkun I, Babu K, Basu S, Carreño E, Lee R, Al-Dhibi H, Bodaghi B, Invernizzi A, Goldstein DA, Herbort CP, Barisani-Asenbauer T, González-López JJ, Androudi S, Bansal R, Moharana B, Mahajan S, Esposti S, Tasiopoulou A, Nadarajah S, Agarwal M, Abraham S, Vala R, Singh R, Sharma A, Sharma K, Zierhut M, Kon OM, Cunningham E, Nguyen QD, Pavesio C, Gupta V.

Ocul Immunol Inflamm. 2017 Dec 20:1-9. doi: 10.1080/09273948.2017.1406529. [Epub ahead of print]

9.

Review for Disease of the Year: Varicella Zoster Virus-Induced Anterior Uveitis.

Tugal-Tutkun I, Cimino L, Akova YA.

Ocul Immunol Inflamm. 2018;26(2):171-177. doi: 10.1080/09273948.2017.1383447. Epub 2017 Oct 12. Review.

PMID:
29023181
10.

Challenges of Diagnosing Viral Anterior Uveitis.

Groen-Hakan F, Babu K, Tugal-Tutkun I, Pathanapithoon K, de Boer JH, Smith JR, de Groot-Mijnes JDF, Rothova A.

Ocul Immunol Inflamm. 2017 Oct;25(5):710-720. doi: 10.1080/09273948.2017.1353105. Epub 2017 Oct 11. Review.

PMID:
29020537
11.

Tocilizumab for the Treatment of Behçet Uveitis that Failed Interferon Alpha and Anti-Tumor Necrosis Factor-Alpha Therapy.

Eser Ozturk H, Oray M, Tugal-Tutkun I.

Ocul Immunol Inflamm. 2018;26(7):1005-1014. doi: 10.1080/09273948.2017.1355471. Epub 2017 Oct 11.

PMID:
29020500
12.

Ophthalmic manifestations of bartonella infection.

Amer R, Tugal-Tutkun I.

Curr Opin Ophthalmol. 2017 Nov;28(6):607-612. doi: 10.1097/ICU.0000000000000419. Review.

PMID:
28984726
13.

Atypical Central Serous Chorioretinopathy.

Cebeci Z, Oray M, Bayraktar Ş, Tuğal-Tutkun İ, Kır N.

Turk J Ophthalmol. 2017 Aug;47(4):238-242. doi: 10.4274/tjo.38039. Epub 2017 Aug 15.

14.

Biologic Treatment Options for Retinal Neovascularization in Behçet's Disease.

Markomichelakis NN, Aissopou EK, Maselos S, Tugal-Tutkun I, Sfikakis PP.

Ocul Immunol Inflamm. 2017 Jul 12:1-7. doi: 10.1080/09273948.2017.1332228. [Epub ahead of print]

PMID:
28700280
15.

Endogenous Brucella endophthalmitis: A case report.

Oray M, Cebeci Z, Kir N, Turgut Ozturk B, Oksuz L, Tugal-Tutkun I.

Saudi J Ophthalmol. 2017 Apr-Jun;31(2):106-108. doi: 10.1016/j.sjopt.2017.03.002. Epub 2017 Mar 12.

16.

Screening for Depression and Anxiety in Patients with Active Uveitis.

Onal S, Oray M, Yasa C, Akman M, Uludag G, Koc Akbay A, Tugal-Tutkun I.

Ocul Immunol Inflamm. 2018;26(7):1078-1093. doi: 10.1080/09273948.2017.1319959. Epub 2017 May 26.

PMID:
28548554
17.

Interferon Alpha for the Treatment of Cystoid Macular Edema Associated with Presumed Ocular Tuberculosis.

Oray M, Onal S, Uludag G, Akbay AK, Tugal-Tutkun I.

J Ocul Pharmacol Ther. 2017 May;33(4):304-312. doi: 10.1089/jop.2016.0097. Epub 2017 Apr 17.

PMID:
28414561
18.

Treatment Results in Serpiginous Choroiditis and Multifocal Serpiginoid Choroiditis Associated with Latent Tuberculosis.

Oray M, Zakiev Z, Çağatay T, Tuğal-Tutkun İ.

Turk J Ophthalmol. 2017 Apr;47(2):89-93. doi: 10.4274/tjo.37630. Epub 2017 Apr 1.

19.

QUANTITATIVE ANALYSIS OF STRUCTURAL ALTERATIONS IN THE CHOROID OF PATIENTS WITH ACTIVE BEHÇET UVEITIS.

Onal S, Uludag G, Oray M, Mengi E, Herbort CP, Akman M, Metin MM, Koc Akbay A, Tugal-Tutkun I.

Retina. 2018 Apr;38(4):828-840. doi: 10.1097/IAE.0000000000001587.

PMID:
28272284
20.

Behçet Uveitis.

Cunningham ET Jr, Tugal-Tutkun I, Khairallah M, Okada AA, Bodaghi B, Zierhut M.

Ocul Immunol Inflamm. 2017 Feb;25(1):2-6. doi: 10.1080/09273948.2017.1279840. No abstract available.

PMID:
28195819
21.

Diverse Clinical Signs of Ocular Involvement in Cat Scratch Disease.

Oray M, Önal S, Koç Akbay A, Tuğal Tutkun İ.

Turk J Ophthalmol. 2017 Jan;47(1):9-17. doi: 10.4274/tjo.28009. Epub 2017 Jan 17.

22.

Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behçet's disease susceptibility.

Takeuchi M, Mizuki N, Meguro A, Ombrello MJ, Kirino Y, Satorius C, Le J, Blake M, Erer B, Kawagoe T, Ustek D, Tugal-Tutkun I, Seyahi E, Ozyazgan Y, Sousa I, Davatchi F, Francisco V, Shahram F, Abdollahi BS, Nadji A, Shafiee NM, Ghaderibarmi F, Ohno S, Ueda A, Ishigatsubo Y, Gadina M, Oliveira SA, Gül A, Kastner DL, Remmers EF.

Nat Genet. 2017 Mar;49(3):438-443. doi: 10.1038/ng.3786. Epub 2017 Feb 6.

23.

Inflammatory eye disease: Pre-treatment assessment of patients prior to commencing immunosuppressive and biologic therapy: Recommendations from an expert committee.

Wakefield D, McCluskey P, Wildner G, Thurau S, Carr G, Chee SP, Forrester J, Dick A, Hudson B, Lightman S, Smith J, Tugal-Tutkun I; pre-treatment assessment Review panel.

Autoimmun Rev. 2017 Mar;16(3):213-222. doi: 10.1016/j.autrev.2017.01.003. Epub 2017 Jan 27. Review.

PMID:
28137477
24.

Failure to Integrate Quantitative Measurement Methods of Ocular Inflammation Hampers Clinical Practice and Trials on New Therapies for Posterior Uveitis.

Herbort CP Jr, Tugal-Tutkun I, Neri P, Pavésio C, Onal S, LeHoang P.

J Ocul Pharmacol Ther. 2017 May;33(4):263-277. doi: 10.1089/jop.2016.0089. Epub 2016 Dec 12. Review.

PMID:
27937751
25.

Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality.

Herbort CP Jr, Abu El Asrar AM, Yamamoto JH, Pavésio CE, Gupta V, Khairallah M, Tugal-Tutkun I, Soheilian M, Takeuchi M, Papadia M.

Int Ophthalmol. 2017 Dec;37(6):1383-1395. doi: 10.1007/s10792-016-0395-0. Epub 2016 Nov 14. Review.

26.

Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis.

Oray M, Tuğal-Tutkun İ.

Turk J Ophthalmol. 2016 Apr;46(2):77-82. Epub 2016 Apr 5. Review.

27.

Evaluation of KIR3DL1/KIR3DS1 polymorphism in Behçet's disease.

Erer B, Takeuchi M, Ustek D, Tugal-Tutkun I, Seyahi E, Özyazgan Y, Duymaz-Tozkir J, Gül A, Kastner DL, Remmers EF, Ombrello MJ.

Genes Immun. 2016 Dec;17(7):396-399. doi: 10.1038/gene.2016.36. Epub 2016 Oct 6.

28.

Systemic vasculitis and the eye.

Tugal-Tutkun I.

Curr Opin Rheumatol. 2017 Jan;29(1):24-32. Review.

PMID:
27662569
29.

Review for Diagnostics of the Year: Multimodal Imaging in Behçet Uveitis.

Tugal-Tutkun I, Ozdal PC, Oray M, Onal S.

Ocul Immunol Inflamm. 2017 Feb;25(1):7-19. doi: 10.1080/09273948.2016.1205100. Epub 2016 Aug 19. Review.

PMID:
27541278
30.

Uveitis in Children and Adolescents.

Cunningham ET Jr, Smith JR, Tugal-Tutkun I, Rothova A, Zierhut M.

Ocul Immunol Inflamm. 2016 Aug;24(4):365-71. doi: 10.1080/09273948.2016.1204777. No abstract available.

PMID:
27471956
31.

Demographic and Clinical Characteristics of Uveitis in Turkey: The First National Registry Report.

Yalçındağ FN, Özdal PC, Özyazgan Y, Batıoğlu F, Tugal-Tutkun I; BUST Study Group.

Ocul Immunol Inflamm. 2018;26(1):17-26. doi: 10.1080/09273948.2016.1196714. Epub 2016 Jul 28.

PMID:
27467500
32.

A single endoplasmic reticulum aminopeptidase-1 protein allotype is a strong risk factor for Behçet's disease in HLA-B*51 carriers.

Takeuchi M, Ombrello MJ, Kirino Y, Erer B, Tugal-Tutkun I, Seyahi E, Özyazgan Y, Watts NR, Gül A, Kastner DL, Remmers EF.

Ann Rheum Dis. 2016 Dec;75(12):2208-2211. doi: 10.1136/annrheumdis-2015-209059. Epub 2016 May 23.

33.
34.

Pars Planitis: Epidemiology, Clinical Characteristics, Management and Visual Prognosis.

Ozdal PC, Berker N, Tugal-Tutkun I.

J Ophthalmic Vis Res. 2015 Oct-Dec;10(4):469-80. doi: 10.4103/2008-322X.176897. Review.

35.

Retinal artery occlusion due to Bartonella henselae infection: a case series.

Eiger-Moscovich M, Amer R, Oray M, Tabbara KF, Tugal-Tutkun I, Kramer M.

Acta Ophthalmol. 2016 Aug;94(5):e367-70. doi: 10.1111/aos.12932. Epub 2016 Jan 8.

36.

Consensus classification criteria for paediatric Behçet's disease from a prospective observational cohort: PEDBD.

Koné-Paut I, Shahram F, Darce-Bello M, Cantarini L, Cimaz R, Gattorno M, Anton J, Hofer M, Chkirate B, Bouayed K, Tugal-Tutkun I, Kuemmerle-Deschner J, Agostini H, Federici S, Arnoux A, Piedvache C, Ozen S; PEDBD group.

Ann Rheum Dis. 2016 Jun;75(6):958-64. doi: 10.1136/annrheumdis-2015-208491. Epub 2015 Dec 23.

37.

Fulminant Ocular Toxoplasmosis: The Hazards of Corticosteroid Monotherapy.

Oray M, Ozdal PC, Cebeci Z, Kir N, Tugal-Tutkun I.

Ocul Immunol Inflamm. 2016 Dec;24(6):637-646. Epub 2015 Dec 8.

PMID:
26647176
38.

Behçet's disease patients with multiple sclerosis-like features: discriminative value of Barkhof criteria.

Akman-Demir G, Mutlu M, Kiyat-Atamer A, Shugaiv E, Kurtuncu M, Tugal-Tutkun I, Tuzun E, Eraksoy M, Bahar S.

Clin Exp Rheumatol. 2015 Nov-Dec;33(6 Suppl 94):S80-4. Epub 2015 Oct 19.

PMID:
26486298
39.

Dexamethasone intravitreal implant (Ozurdex®) for pediatric uveitis.

Sella R, Oray M, Friling R, Umar L, Tugal-Tutkun I, Kramer M.

Graefes Arch Clin Exp Ophthalmol. 2015 Oct;253(10):1777-82. doi: 10.1007/s00417-015-3124-x. Epub 2015 Jul 31.

PMID:
26228441
40.

Natural killer cells dominate a Th-1 polarized response in Behçet's disease patients with uveitis.

Kucuksezer UC, Aktas-Cetin E, Bilgic-Gazioglu S, Tugal-Tutkun I, Gül A, Deniz G.

Clin Exp Rheumatol. 2015 Nov-Dec;33(6 Suppl 94):S24-9. Epub 2015 Apr 28.

PMID:
25937098
41.

Acute granulomatous iridocyclitis in a child with tubulointerstitial nephritis and uveitis syndrome.

Barut K, Rzayev T, Canpolat N, Ozluk Y, Tugal-Tutkun I, Kasapcopur O.

J Ophthalmic Inflamm Infect. 2015 Feb 13;5:3. doi: 10.1186/s12348-015-0035-2. eCollection 2015.

42.

Update on uveitis management.

Gupta V, Nguyen QD, Zierhut M, Tugal-Tutkun I.

J Ophthalmol. 2015;2015:382747. doi: 10.1155/2015/382747. Epub 2015 Feb 23. No abstract available.

43.

Anti-interferon alpha antibodies and autoantibodies in patients with Behçet's disease uveitis treated with recombinant human interferon alpha-2a.

Aydinoglu-Candan Ö, Araz-Erşan B, Gul A, Badur S, Tugal-Tutkun I.

Graefes Arch Clin Exp Ophthalmol. 2015 Mar;253(3):457-65. doi: 10.1007/s00417-014-2856-3. Epub 2014 Dec 12.

PMID:
25500983
44.

Nonglaucomatous localized retinal nerve fiber layer defects in Behçet uveitis.

Oray M, Onal S, Bayraktar S, Izgi B, Tugal-Tutkun I.

Am J Ophthalmol. 2015 Mar;159(3):475-81.e1. doi: 10.1016/j.ajo.2014.11.029. Epub 2014 Nov 26.

PMID:
25461299
45.

Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study.

Riemens A, Bromberg J, Touitou V, Sobolewska B, Missotten T, Baarsma S, Hoyng C, Cordero-Coma M, Tomkins-Netzer O, Rozalski A, Tugal-Tutkun I, Guex-Crosier Y, Los LI, Bollemeijer JG, Nolan A, Pawade J, Willermain F, Bodaghi B, ten Dam-van Loon N, Dick A, Zierhut M, Lightman S, Mackensen F, Moulin A, Erckens R, Wensing B, le Hoang P, Lokhorst H, Rothova A.

JAMA Ophthalmol. 2015 Feb;133(2):191-7. doi: 10.1001/jamaophthalmol.2014.4755.

46.

Intravitreal dexamethasone implant (Ozurdex) and photodynamic therapy for vasoproliferative retinal tumours.

Cebeci Z, Oray M, Tuncer S, Tugal Tutkun I, Kir N.

Can J Ophthalmol. 2014 Aug;49(4):e83-4. doi: 10.1016/j.jcjo.2014.04.006. Epub 2014 Jul 17. No abstract available.

PMID:
25103664
47.

Re: Levy-Clarke et al.: Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders (Ophthalmology 2014;121:785-96).

Onal S, Tugal-Tutkun I.

Ophthalmology. 2014 Oct;121(10):e57-8. doi: 10.1016/j.ophtha.2014.05.033. Epub 2014 Jul 23. No abstract available.

PMID:
25064722
48.

Vogt-Koyanagi-Harada disease.

Cunningham ET Jr, Rathinam SR, Tugal-Tutkun I, Muccioli C, Zierhut M.

Ocul Immunol Inflamm. 2014 Aug;22(4):249-52. doi: 10.3109/09273948.2014.939530. Review. No abstract available.

PMID:
25014114
49.

Uveitis as a prognostic factor in multiple sclerosis.

Shugaiv E, Tüzün E, Kürtüncü M, Kıyat-Atamer A, Çoban A, Akman-Demir G, Tugal-Tutkun I, Eraksoy M.

Mult Scler. 2015 Jan;21(1):105-7. doi: 10.1177/1352458514539782. Epub 2014 Jun 16.

PMID:
24948689
50.

Bilateral acute iris transillumination following a fumigation therapy: a village-based traditional method for the treatment of ophthalmomyiasis.

Gonul S, Bozkurt B, Okudan S, Tugal-Tutkun I.

Cutan Ocul Toxicol. 2015 Mar;34(1):80-3. doi: 10.3109/15569527.2014.886589. Epub 2014 Mar 31.

PMID:
24678751

Supplemental Content

Loading ...
Support Center